Corbus Pharmaceuticals Holding (CRBP) Stock Analysis — PE Ratio, PS Ratio, Intrinsic Value & 2030 Price Target
Corbus Pharmaceuticals Holding stock (CRBP) is currently trading at $8.18. Corbus Pharmaceuticals Holding PS ratio (Price-to-Sales) is 163.32. Analyst consensus price target for CRBP is $42.11. WallStSmart rates CRBP as Sell.
- CRBP PE ratio analysis and historical PE chart
- CRBP PS ratio (Price-to-Sales) history and trend
- CRBP intrinsic value — DCF, Graham Number, EPV models
- CRBP stock price prediction 2025 2026 2027 2028 2029 2030
- CRBP fair value vs current price
- CRBP insider transactions and insider buying
- Is CRBP undervalued or overvalued?
- Corbus Pharmaceuticals Holding financial analysis — revenue, earnings, cash flow
- CRBP Piotroski F-Score and Altman Z-Score
- CRBP analyst price target and Smart Rating
Corbus Pharmaceuticals Holding
📊 No data available
Try selecting a different time range
Smart Analysis
Corbus Pharmaceuticals Holding (CRBP) · 6 metrics scored
Smart Score
Category Performance
WallStSmart pulls financial metrics like revenue growth, profit margins, and valuation ratios and scores each one from 0 to 10 based on how strong or weak it is. Those 10 scores are grouped into 4 categories: Growth, Profitability, Valuation, and Quality — which form the 4 axes of the spider chart you see. The categories are then combined into a final score out of 100, but not equally. Growth and Profitability together count for 60% of the total, because a fast-growing profitable business matters more than just a cheap one. That final number maps to a rating (Strong Buy, Buy, Hold, Avoid) and a letter grade, giving you one clear Stock Rating.
Investment Thesis
Strong fundamentals in price/book, institutional own.. Concerns around market cap and return on equity. Significant fundamental concerns warrant caution or avoidance.
Corbus Pharmaceuticals Holding (CRBP) Key Strengths (2)
75.83% of shares held by major funds and institutions
Trading at 1.63x book value, attractively priced
Supporting Valuation Data
Corbus Pharmaceuticals Holding (CRBP) Areas to Watch (4)
Company is destroying shareholder value
Revenue declining -100.00%, a shrinking business
Very expensive at 163.3x annual revenue
Micro-cap company with very limited liquidity and high volatility
Supporting Valuation Data
Corbus Pharmaceuticals Holding (CRBP) Detailed Analysis Report
Overall Assessment
This company scores 22/100 in our Smart Analysis, earning a F grade. Out of 6 metrics analyzed, 2 register as strengths (avg 9.0/10) while 4 fall into concern territory (avg 1.3/10). The category breakdown reveals uneven performance, with some areas requiring attention.
The Bull Case
The strongest argument centers on Institutional Own., Price/Book. Valuation metrics including Price/Book (1.63) suggest the stock is attractively priced.
The Bear Case
The primary concerns are Return on Equity, Revenue Growth, Price/Sales. Some valuation metrics including Price/Sales (163.32) suggest expensive pricing. Growth concerns include Revenue Growth at -100.00%, which may limit upside. Profitability pressure is visible in Return on Equity at -54.20%.
Key Dynamics to Monitor
Three factors to monitor going forward. First, whether Return on Equity improves, as this is the primary drag on the overall score. Second, margin trajectory, with Return on Equity at -54.20% needing improvement to support the investment thesis. Third, growth sustainability, with Revenue Growth at -100.00% needing to reaccelerate.
Risk Considerations
Based on the metric profile, this is a higher risk investment. There are more areas of concern than strength, warranting a more conservative position size. Investors should size positions according to their risk tolerance and maintain diversification.
Bottom Line
Fundamental challenges outweigh strengths at current levels. Return on Equity and Revenue Growth are the primary drags. Consider waiting for meaningful improvement before committing capital.
Disclaimer: Smart Analysis is a scoring system developed by WallStSmart Team. Scores update daily using multi-model valuation framework. Always conduct your own research and consult with financial advisors before making investment decisions.
CRBP Price-to-Sales(PS) Ratio Chart
Historical valuation based on market cap ÷ trailing 12-month revenue
CRBP's Price-to-Sales ratio of 163.32x trades at a 31% premium to its historical average of 125.04x (75th percentile). The current valuation is 87% below its historical high of 1217.97x set in Aug 2024, and 35404% above its historical low of 0.46x in Oct 2020. Over the past 12 months, the PS ratio has expanded from ~109.9x, reflecting growing market expectations outpacing revenue growth.
WallStSmart Analysis Synopsis
Data-driven financial summary for Corbus Pharmaceuticals Holding (CRBP) · HEALTHCARE › BIOTECHNOLOGY
The Big Picture
Corbus Pharmaceuticals Holding operates as a stable business with moderate growth and solid fundamentals. The company is currently unprofitable, posting a 0.0% profit margin.
Key Findings
Revenue contracted 100% YoY. Worth determining whether this is cyclical or structural.
Free cash flow is -16M, meaning the company is burning cash. This may be acceptable for high-growth companies investing heavily.
What to Watch Next
Volatility is elevated with a beta of 2.91, so expect amplified moves relative to the broader market.
Sector dynamics: monitor BIOTECHNOLOGY industry trends, competitive moves, and regulatory changes that could impact Corbus Pharmaceuticals Holding.
Bottom Line
Corbus Pharmaceuticals Holding offers stability with moderate growth and solid fundamentals. The valuation may present an opportunity for patient investors, though limited growth means returns will likely come from dividends and modest capital appreciation rather than explosive gains.
This synopsis is generated from publicly available financial data. It is not financial advice. Always conduct your own research and consult a qualified financial advisor before making investment decisions.
Insider Transactions(14 last 3 months)
| Insider | Type | Shares |
|---|---|---|
SMETHURST, DOMINIC Chief Medical Officer | Sell | -6,097 |
| Insider | Type | Shares |
|---|---|---|
HODGSON, IAN Chief Operating Officer | Sell | -847 |
Data sourced from SEC Form 4 filings
Last updated: 8:28:06 AM
About Corbus Pharmaceuticals Holding(CRBP)
NASDAQ
HEALTHCARE
BIOTECHNOLOGY
USA
Corbus Pharmaceuticals Holdings, Inc., a clinical-stage pharmaceutical company, focuses on the development and commercialization of novel therapies that target the endocannabinoid system in the fields of autoimmunity, fibrosis, and cancer. The company is headquartered in Norwood, Massachusetts.